兴齐眼药股价跌5.1%，南方基金旗下1只基金位居十大流通股东，持有251.63万股浮亏损失918.46万元

Core Viewpoint - On September 19, Xingqi Eye Pharmaceutical experienced a decline of 5.1%, with a stock price of 67.96 yuan per share, a trading volume of 872 million yuan, a turnover rate of 6.64%, and a total market capitalization of 16.674 billion yuan [1] Company Overview - Xingqi Eye Pharmaceutical Co., Ltd. is located in Shenyang, Liaoning Province, and was established on March 24, 1977, with its listing date on December 8, 2016 [1] - The company's main business involves the research, production, and sales of ophthalmic drugs, with revenue composition as follows: eye drops 82.15%, gel/eye ointment 16.70%, and others 1.15% [1] Shareholder Information - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2.5163 million shares, which represents 1.34% of the circulating shares [2] - The estimated floating loss for the ETF today is approximately 9.1846 million yuan [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion yuan, and has achieved a year-to-date return of 27.4% [2] Fund Performance - The Southern Big Data 300 Index A (001420) holds 47,800 shares of Xingqi Eye Pharmaceutical, accounting for 0.93% of the fund's net value, ranking as the seventh largest holding [3] - The estimated floating loss for this fund today is about 174,300 yuan [3] - The Southern Big Data 300 Index A was established on June 24, 2015, with a latest scale of 2.17 billion yuan, and has achieved a year-to-date return of 37% [3]